{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:03:02Z","timestamp":1790643782465,"version":"4.1.0"},"reference-count":12,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Pathol"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Loncastuximab tesirine (LT) is an antibody\u2010drug conjugate (ADC), a novel class of therapeutics that combines a target\u2010specific monoclonal antibody with a cytotoxic agent via a chemical linker. LT has been approved in the United States as therapy for relapsed or refractory diffuse large B\u2010cell lymphoma (DLBCL). Given the novelty of this drug, cutaneous adverse effects remain poorly characterized. In this case report, we present a 35\u2010year\u2010old male with relapsing and refractory DLBCL who developed a bullous eruption after his third cycle of LT. Physical exam revealed scattered erosions and erythema of the neck and extremities, along with multiple bullae and erosions on the hands and dorsal feet, and vesicles on the shin. Histopathological exam revealed basovacuolar alteration with epidermal dysmaturation and a re\u2010epithelializing blister, features suggestive of toxic erythema of chemotherapy (TEC). Direct immunofluorescence was negative for immune complex deposition. To date, there are only three cases of LT\u2010associated bullous eruptions in the literature, all demonstrating subepidermal blistering with granular IgA deposition along the basement membrane. This case lacks immunoglobulin deposition and instead exhibits TEC\u2010like cytotoxic interface dermatitis. This case expands the clinicopathologic spectrum of LT\u2010associated cutaneous toxicity and highlights a distinct non\u2010immune mediated, TEC\u2010like vesiculobullous presentation.<\/jats:p>","DOI":"10.1111\/cup.70220","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:45:36Z","timestamp":1790642736000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bullous Eruption Associated With Loncastuximab Tesirine in a Patient With Diffuse Large B\u2010Cell Lymphoma"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4444-0640","authenticated-orcid":false,"given":"Daniella","family":"Jaguan","sequence":"first","affiliation":[{"name":"Department of Dermatology Northwestern University Feinberg School of Medicine  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6543-5748","authenticated-orcid":false,"given":"Cuong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Dermatology Northwestern University Feinberg School of Medicine  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer N.","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Dermatology Northwestern University Feinberg School of Medicine  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"1","key":"e_1_2_10_2_1","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1951427","article-title":"Targeting Cancer With Antibody\u2010Drug Conjugates: Promises and Challenges","volume":"13","author":"Dean A. Q.","year":"2021","journal-title":"MAbs"},{"issue":"8","key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site\u2010Specific Conjugation of a Cytotoxic Drug to an Antibody Improves the Therapeutic Index","volume":"26","author":"Junutula J. R.","year":"2008","journal-title":"Nature Biotechnology"},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1203073","article-title":"Antibody\u2010Drug Conjugates: The Paradigm Shifts in the Targeted Cancer Therapy","volume":"14","author":"Aggarwal D.","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab Tesirine in Relapsed or Refractory Diffuse Large B\u2010Cell Lymphoma (LOTIS\u20102): A Multicentre, Open\u2010Label, Single\u2010Arm, Phase 2 Trial","volume":"22","author":"Caimi P. F.","year":"2021","journal-title":"Lancet Oncology"},{"issue":"4","key":"e_1_2_10_6_1","first-page":"303","article-title":"The Antibody\u2010Drug Conjugate Loncastuximab Tesirine for the Treatment of Diffuse Large B\u2010Cell Lymphoma","volume":"140","author":"Calabretta E.","year":"2022","journal-title":"Blood"},{"issue":"10","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.3324\/haematol.2023.284197","article-title":"Targeting CD19\u2010Positive Lymphomas With the Antibodydrug Conjugate Loncastuximab Tesirine: Preclinical Evidence of Activity as a Single Agent and in Combination Therapy","volume":"109","author":"Tarantelli C.","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_10_8_1","unstructured":"ADC Therapeutics SA \u201cZynlonta (Loncastuximab Tesirine\u2010lpyl) Prescribing Information \u201d(2021) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761196s000lbl.pdf."},{"issue":"19","key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed\/Refractory B\u2010Cell Non\u2010Hodgkin Lymphoma","volume":"137","author":"Hamadani M.","year":"2021","journal-title":"Blood"},{"issue":"7","key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamadermatol.2022.1389","article-title":"Blistering Lesions Associated With Loncastuximab Tesirine","volume":"158","author":"Gociman S.","year":"2022","journal-title":"JAMA Dermatology"},{"key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdcr.2024.08.013","article-title":"Vesiculobullous Eruption With Loncastuximab Tesirine in a Patient With Relapsed Follicular Lymphoma","volume":"53","author":"Seervai R. N. H.","year":"2024","journal-title":"JAAD Case Reports"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2025.05.003"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000002255"}],"container-title":["Journal of Cutaneous Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cup.70220","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cup.70220","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cup.70220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:45:38Z","timestamp":1790642738000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cup.70220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":12,"alternative-id":["10.1111\/cup.70220"],"URL":"https:\/\/doi.org\/10.1111\/cup.70220","archive":["Portico"],"relation":{},"ISSN":["0303-6987","1600-0560"],"issn-type":[{"value":"0303-6987","type":"print"},{"value":"1600-0560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"2026-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"cup.70220"}}